Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus
However, depending on their BMI and weight loss goals, some members may be prescribed fat absorption blockers or appetite suppressants
H., Sanada, T., Kohara, M
Summary Keywords GLP 1, nausea & vomiting, obesity, semaglutide, side effect, tirzepatide Citation Alhazmi A and le Roux CW (2026) Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
This supplement should be taken as part of a varied, balanced diet and healthy lifestyle
Although todays semaglutide market is largely OOP, falling costs could tip the scales for wider public reimbursement where insurers may be more willing to cover AOMs, in addition to simplifying coverage by removing restrictions such as prior authorisation (see section above on public reimbursement)